Identifying Splicing Factors Critical for Androgen Receptor Variant Generation in Prostate Cancer

Prostate cancer kills 12,000 men in the UK each year and requires new, more effective treatments. Androgen receptor splice variants drive fatal disease progression and represent a major clinical challenge. This project will investigate the generation of androgen receptor variants in contemporary models of advanced prostate cancer that will fill a critical knowledge gap in this field and provide new targets for therapy.
Cross-disciplinary training will be provided in high-throughput screening platforms and bespoke molecular/cellular biology techniques across the two sites at the Northern Institute for Cancer Research, Newcastle University and within Discovery Sciences, AstraZeneca, Cambridge. As part of the BBSRC collaborative training partnership, you will spend at least three months at AstraZeneca where you will gain invaluable experience working in an industrial setting